drugset / Trial / NCT00069849

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

NCT00069849

Phase 2 Terminated 64 enrolled Abbott
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

Timeline

Start
2003-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozanicline Small molecule 2 mg
Subject Pozanicline Small molecule 4 mg
Subject Pozanicline Small molecule 20 mg

Indications